TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +20.00% and -21.61%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?